IPO Year: 2018
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | Buy | TD Cowen | |
| 10/3/2024 | $48.00 | Outperform | Oppenheimer |
| 7/26/2024 | $58.00 | Outperform | Robert W. Baird |
| 6/27/2024 | Overweight | Cantor Fitzgerald | |
| 5/16/2024 | $40.00 | Buy | H.C. Wainwright |
| 2/15/2024 | $44.00 | Buy | Stifel |
| 12/26/2023 | $22.00 | Buy | Jefferies |
| 11/22/2023 | $23.00 | Outperform | Wedbush |
| 10/30/2023 | $45.00 | Buy | Guggenheim |
| 9/28/2023 | $24.00 | Outperform | Raymond James |
TD Cowen initiated coverage of Dianthus Therapeutics with a rating of Buy
Oppenheimer initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $48.00
Robert W. Baird initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $58.00
Cantor Fitzgerald initiated coverage of Dianthus Therapeutics with a rating of Overweight
H.C. Wainwright initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $40.00
Stifel initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $44.00
Jefferies initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $22.00
Wedbush initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $23.00
Guggenheim initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $45.00
Raymond James initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $24.00
Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion Mr. King also led the commercial strategy behind the first FDA-approved, self-administered, subcutaneous biologic for gMG as the Chief Commercial Officer of Ra Pharma, acquired by UCB for $2.5 billion Mr. Kango has >26 years of industry experience spanning senior executive, commercial and business development roles in the pharmaceutical and biotechnology sector NEW YORK and WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology co
Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President, Head of Investor Relations & Corporate Affairs with over 20 years of experience at leading public biopharmaceutical companies NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr.
10-Q - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
SCHEDULE 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SCHEDULE 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
DEFA14A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
DEF 14A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
S-8 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
10-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular franchise by YE'26 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $331.5 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage
MaGic trial exceeded enrollment target of 60 patients Top-line results anticipated this September will be the first of three DNTH103 catalysts by YE'26 Building a neuromuscular franchise with DNTH103 in gMG, CIDP and MMN with a potential best-in-class, potent classical pathway inhibitor intended as a self-administered autoinjector dosed once every two weeks NEW YORK and WALTHAM, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced completion of enrollment in the Phase 2 MaGic trial of DNTH
NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at two upcoming investor events. Baird Biotech Discovery Series - Marino Garcia, Chief Executive Officer, will participate in a fireside chat webcast on Tuesday, May 6 at 1:30 p.m. EDT.Bank of America 2025 Health Care Conference – Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, May 14 at 5:35 p.m. EDT / 2:35 p.m. PDT and will host one-on-one meeting
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H'26 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 $357.0 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmu
Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion Mr. King also led the commercial strategy behind the first FDA-approved, self-administered, subcutaneous biologic for gMG as the Chief Commercial Officer of Ra Pharma, acquired by UCB for $2.5 billion Mr. Kango has >26 years of industry experience spanning senior executive, commercial and business development roles in the pharmaceutical and biotechnology sector NEW YORK and WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology co
NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the following investor conferences: TD Cowen 45th Annual Health Care Conference – Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Wednesday, March 5 at 11:50 a.m. ET and host one-on-one meetings with investors in Boston. A webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website.Jeff
NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February: Guggenheim SMID Cap Biotech Conference – Fireside chat on February 6 at 9:00 a.m. ET in New York CityOppenheimer 35th Annual Healthcare Life Sciences Conference – Fireside chat on February 12 at 3:20 p.m. ET, taking place virtually Live webcasts of th
NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the 43rd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco. A live webcast of the Company's presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About Dianthus TherapeuticsDiant
Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE'24 Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H'25 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 Approximately $343 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmu
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024: Guggenheim Healthcare Innovation Conference on November 11 at 1:30 p.m. ET in Boston, MAJefferies Global Healthcare Conference on November 19 at 9:00 a.m. GMT in London7th Annual Evercore HealthCONx Conference on December 4 at 1
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
3 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
3 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)